Pathogenesis of prolactinomas

Research output: Contribution to journalArticle

Abstract

In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes. However, with the exception of one RAS mutation identified in a single unusually aggressive prolactinoma resistant to dopaminergic inhibition that resulted to be lethal, no mutational changes have been so far detected in prolactinomas. In the absence of genetic changes, modifications in the level of expression of oncogenes or tumor suppressor genes have been detected in these tumors, although it is unknown whether these changes have a causative role or are a secondary event. Indeed, our knowledge on the molecular events involved in lactotroph proliferation is even more limited in comparison to the other tumor types, since these tumors are very infrequently surgically removed and therefore available for molecular biology studies. In this respec, it is worth noting that the molecular and biological abnormalities so far described in prolactinomas mainly concern aggressive and atypical tumors and likely do not apply to the typical prolactinomas, that are characterized by good response to medical treatment and a very low growth rate.

Original languageEnglish
Pages (from-to)7-15
Number of pages9
JournalPituitary
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Prolactinoma
Neoplasms
Tumor Suppressor Genes
Lactotrophs
Proto-Oncogenes
Pituitary Neoplasms
Growth
Oncogenes
Molecular Biology
Mutation

Keywords

  • D2 receptor
  • Growth factors
  • Oncogenes
  • PRL-omas
  • Tumor suppressor genes

ASJC Scopus subject areas

  • Endocrinology

Cite this

Pathogenesis of prolactinomas. / Spada, Anna; Mantovani, Giovanna; Lania, Andrea.

In: Pituitary, Vol. 8, No. 1, 01.2005, p. 7-15.

Research output: Contribution to journalArticle

Spada, Anna ; Mantovani, Giovanna ; Lania, Andrea. / Pathogenesis of prolactinomas. In: Pituitary. 2005 ; Vol. 8, No. 1. pp. 7-15.
@article{6de23bade9304832be39d0b271b7c523,
title = "Pathogenesis of prolactinomas",
abstract = "In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes. However, with the exception of one RAS mutation identified in a single unusually aggressive prolactinoma resistant to dopaminergic inhibition that resulted to be lethal, no mutational changes have been so far detected in prolactinomas. In the absence of genetic changes, modifications in the level of expression of oncogenes or tumor suppressor genes have been detected in these tumors, although it is unknown whether these changes have a causative role or are a secondary event. Indeed, our knowledge on the molecular events involved in lactotroph proliferation is even more limited in comparison to the other tumor types, since these tumors are very infrequently surgically removed and therefore available for molecular biology studies. In this respec, it is worth noting that the molecular and biological abnormalities so far described in prolactinomas mainly concern aggressive and atypical tumors and likely do not apply to the typical prolactinomas, that are characterized by good response to medical treatment and a very low growth rate.",
keywords = "D2 receptor, Growth factors, Oncogenes, PRL-omas, Tumor suppressor genes",
author = "Anna Spada and Giovanna Mantovani and Andrea Lania",
year = "2005",
month = "1",
doi = "10.1007/s11102-005-5080-7",
language = "English",
volume = "8",
pages = "7--15",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Pathogenesis of prolactinomas

AU - Spada, Anna

AU - Mantovani, Giovanna

AU - Lania, Andrea

PY - 2005/1

Y1 - 2005/1

N2 - In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes. However, with the exception of one RAS mutation identified in a single unusually aggressive prolactinoma resistant to dopaminergic inhibition that resulted to be lethal, no mutational changes have been so far detected in prolactinomas. In the absence of genetic changes, modifications in the level of expression of oncogenes or tumor suppressor genes have been detected in these tumors, although it is unknown whether these changes have a causative role or are a secondary event. Indeed, our knowledge on the molecular events involved in lactotroph proliferation is even more limited in comparison to the other tumor types, since these tumors are very infrequently surgically removed and therefore available for molecular biology studies. In this respec, it is worth noting that the molecular and biological abnormalities so far described in prolactinomas mainly concern aggressive and atypical tumors and likely do not apply to the typical prolactinomas, that are characterized by good response to medical treatment and a very low growth rate.

AB - In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes. However, with the exception of one RAS mutation identified in a single unusually aggressive prolactinoma resistant to dopaminergic inhibition that resulted to be lethal, no mutational changes have been so far detected in prolactinomas. In the absence of genetic changes, modifications in the level of expression of oncogenes or tumor suppressor genes have been detected in these tumors, although it is unknown whether these changes have a causative role or are a secondary event. Indeed, our knowledge on the molecular events involved in lactotroph proliferation is even more limited in comparison to the other tumor types, since these tumors are very infrequently surgically removed and therefore available for molecular biology studies. In this respec, it is worth noting that the molecular and biological abnormalities so far described in prolactinomas mainly concern aggressive and atypical tumors and likely do not apply to the typical prolactinomas, that are characterized by good response to medical treatment and a very low growth rate.

KW - D2 receptor

KW - Growth factors

KW - Oncogenes

KW - PRL-omas

KW - Tumor suppressor genes

UR - http://www.scopus.com/inward/record.url?scp=33644856993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644856993&partnerID=8YFLogxK

U2 - 10.1007/s11102-005-5080-7

DO - 10.1007/s11102-005-5080-7

M3 - Article

C2 - 16411063

AN - SCOPUS:33644856993

VL - 8

SP - 7

EP - 15

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 1

ER -